Updates are available Correction dated 2023-06-05

Article History

Received: 14 April 2023

Accepted: 16 April 2023

First Online: 6 May 2023

Change Date: 5 June 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12094-023-03229-y

Declarations

:

: JAG-S reports Advisory Board and Speaker from Novartis, Lilly, Daiichi Sankyo, Gilead; Advisory Board from AstraZeneca, Pierre Fabre, EISAI; Grant from Seagen; Speaker from Roche, Asofarma and Exact Sciences and Advisory Board and Grant from Stemline Menarini. IBL-B reports Advisory Board, Speaker and Grant from Roche, Lilly and Astrazeneca; Advisory Board and Speaker from Novartis, Celgene, Eisai, Pierre Fabre, BMS, Daiichi Sankyo, Grünenthal, Seagen and Veracyte and Grant from Agendia. IE reports Advisory Board and Speaker from Lilly, Speaker from Pfizer, Novartis; Advisory Board from AstraZeneca; Speaker from Roche and Pierre Fabre. MMV reports Advisory Board from Gilead, Lilly Piere Fabre Daichy Eisai; Grant from Pfizer and Speaker from Pierre Fabre. FMA reports Advisory Board, Speaker, Grant and others from Pfizer; Advisory Board from Novartis, Daiichi Sankyo, Astra Zeneca; Others from MSD, Pierre Fabre, Gilead, Seagen and Roche. SP reports Advisory Board, Speaker and Non-financial Support from AstraZeneca and Daiichi; Advisory Board and Grant from Roche; Speaker and Non-financial Support from Lilly and Novartis; Advisory Board from Pierre Fabre and Seagen; Non-financial Support from Gilead; Advisory Board and Non-financial Support from Pfizer and Speaker from Eisai. MBE reports Speaker from Pfizer, Lilly, Novartis; Advisory Board from Pfizer, Lilly, Novartis and Stemline Menarini and Travel Expenses from Pfizer. CH, TRC, and NR have nothing to disclose.

: As this manuscript is not a clinical trial but a review article, no ethical approval and informed consent is needed.